Breast Cancer Foundation NZ
Overcoming aromatase inhibitor resistance in patients with ER+ breast cancer
June 2011
Research Grant
What is the problem and who is affected?
Aromatase inhibitors (AIs), or anti-estrogens, are the common treatment for patients with estrogen receptor-positive (ER+) cancers. It is almost inevitable, however, that secondary therapy will be required as most patients develop a resistance to the AIs.
What is this research hoping to achieve?
Dr Leung and her team will investigate the use of inhibitors of the PI3K/mTOR pathway, using several candidate drugs, as a way to prevent AI resistance.